10 Biggest Biotechnology Companies

As a result of the COVID-19 epidemic, companies that specialize in biotechnology have assumed a more prominent role in the pharmaceutical industry. Through the rapid development of diagnostic tests and vaccinations, numerous biotechnology companies around the world have contributed to the global effort to combat the COVID-19 virus.

Especially in recent years, we have seen several exciting developments in this field, such as the application of AI platforms to drug discovery, the introduction of RNA-based therapeutics and single-cell genomics, and the development of bio-based manufacturing. Because of these improvements, the businesses have made progress in their medication research and commercialization efforts, particularly in the illness areas with high unmet needs.

We looked at the multiple important characteristics in their product line for this compiled list and the therapeutic areas they concentrate on. Here is a list of the 10 biggest biotechnology companies:

Novo Nordisk

Novo Nordisk has earned 18.3 billion US dollars in revenue (TTM). Also, 5.8 billion US dollars in annualized net income.

It is a Danish-based international biotechnology corporation and one of the biggest biotech companies. Novo Nordisk sells its wares in over 160 countries worldwide. Its headquarters are located in Copenhagen.

Diabetes is the principal research interest of the firm. It has created sixteen production facilities located in nine different countries. In addition, the company has ten research and development sites across five different nations.

In addition, the business is involved in the research, development, and marketing of medications that treat hemophilia and other uncommon bleeding illnesses and growth hormone deficiency, and obesity. Some of the main portfolios of biotechnology products are Levemir, NovoLog, NovoSeven, Novolin R, and Victozahave, which the company has successfully brought to market.

Regeneron Pharmaceuticals

Total (TTM) revenue of Regeneron is 7.9 billion US dollars and annualized Net Profit is 2.1 Billion.

Regeneron Pharmaceuticals is engaged in the process of discovering new biopharmaceutical drugs along with manufacturing new ones and marketing them as well. The treatment of eye illnesses, cardiovascular diseases, allergy, and inflammatory concerns, cancer, and infectious disorders are the primary focuses of Regeneron's research and development.

It has formed strategic alliances with a number of the world's most well-known pharmaceutical companies to create and sell innovative drugs. A Regeneron Genetics Laboratory has also been built by the business, and its primary mission is to carry out one of the most extensive genes sequencing operations ever attempted.

Alexion Pharmaceuticals

TTM revenue of Alexion is 5.0 billion US dollars and their Net Income is USD 2.4 billion.

Alexion is a multinational pharmaceutical company division and includes in the list of largest biotech companies AstraZeneca which is exclusively devoted to the research and development of treatments for uncommon diseases.

The firm has five medications on the market for patients with PNH, which include:

• AHUS-atypical hemolytic uremic syndrome
• AQP4- Anti-aquaporin-4
• NMOSD- Antibody-positive neuromyelitis optica spectrum disease
• gMG- generalized Myasthenia Gravis
• HPP- Hypophosphatasia (HPP)
• LAL-D lysosomal acid lipase deficiency

Alexion's therapeutic prospects attempt to produce pharmacological molecules that specifically target specific components of the immune system that are important for disease progression.

Vertex Pharmaceuticals

TTM revenue of Vertex is 4.2 billion US dollars and their Net Income is USD 1.2 billion.

Vertex is an international biotechnology business that focuses on researching and developing life-changing treatments for patients suffering from critical illnesses. The company has many medications authorized to cure cystic fibrosis, which is an extremely uncommon genetic condition that can be fatal. The current location of the company's international headquarters has been in London since it was established in 1989.

Moreover, the corporation maintains commercial and research and development offices in other countries, including North America, Europe, Australia, and Latin America. The firm focuses on creating treatments for additional malignant indications, autoimmune illnesses, and neurological disorders in conjunction with cystic fibrosis as one of its primary areas of research and development.

Jazz Pharmaceuticals

TTM revenue of jazz pharmaceuticals is 2.2 billion US dollars and their Net Income is USD 0.5 billion.

Jazz Pharmaceuticals is a Dublin-based company that focuses on developing innovative pharmaceutical candidates in two main therapeutic areas: neurology and cancer.

Its marketed products include those used to treat narcolepsy, psychiatry, pain management, and cancer. Furthermore, the firm claims to be a pioneer in biotechnology, sleep disturbances, epilepsy, hematologic malignancy, and solid tumors. The business intends to use cannabinoid science and revolutionary delivery technology to produce new molecules.

Incyte Corporation

TTM revenue of invite corporation is 2.2 billion US dollars and their Net Income is USD 0.5 billion.

Incyte is a biotechnology company responsible for discovering new biological medicines, developing such therapies, and then commercializing them. The business has a medication candidate called Jakafi that has been given the green light for use in curing myelofibrosis. A rising number of potential treatments in oncology and inflammation and autoimmunity are in the development stages at this firm.

Biomarin Pharmaceutical

TTM revenue of Biomarin is 1.7 billion USD. Also, BioMarin is established in 1997, is a pioneer in the research and marketing of best-in-class medicines for rare genetic illnesses. Biomarin Pharmaceutical has created several therapeutic enzyme medicines to treat lysosomal storage illnesses and severe burn injuries. PALYNZIQ, Brineura, Vimizim, Kuvan, Naglazyme, and Aldurazyme are among the authorized drugs of the firm.

United Therapeutics

The total TTM Turnover of United Therapeutics is USD 1.4 billion.

United Therapeutics is actively working on researching and developing potential treatments for pulmonary arterial hypertension, peripheral vascular disease, and other disorders related to the cardiovascular system. The firm's primary goals are the creation of innovative pharmacological treatments and the development of technology to facilitate the simpler availability of organs that can be transplanted.

Alkermes

The total TTM Turnover of Alkermes is USD 1.2 billion.

It is an Irish pharmaceutical business named Alkermes that focuses on developing therapeutic therapies for diseases of the central nervous system, such as mental illnesses such as depression and schizophrenia, as well as addiction. In addition, the firm is working on the research and development of new medicines for the treatment of diabetes.

Ionis Pharmaceuticals

Total TTM Turnover of Ionisis USD 0.3 billion. Ionis Pharmaceuticals is dedicated to researching and developing pharmaceutical solutions based on RNA. It has three key medications that are now accessible on the commercial market: WAYLIVRA, Spinraza, and Tegsedi. In addition, the business is working on developing medicines for Huntington's disease, amyotrophic lateral sclerosis (ALS), and cardiovascular disease with the hope of one day commercializing them.